{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T20:52:24Z","timestamp":1782766344669,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We have analyzed the histopathological, clinical, and genetic characteristics in hereditary breast and ovarian cancer patients of counselled families from 1996 up to today in the southwestern Finland population. In this study we analyzed the incidence of different <jats:italic>BRCA1<\/jats:italic> and <jats:italic>BRCA2<\/jats:italic> pathogenic variants (PV). 1211 families were evaluated, and the families were classified as 38 <jats:italic>BRCA1<\/jats:italic> families, 48 <jats:italic>BRCA2<\/jats:italic> families, 689 non-<jats:italic>BRCA<\/jats:italic> families and 436 other counselled families (criteria for genetic testing was not met). In those families, the study consisted of 44 <jats:italic>BRCA1<\/jats:italic> breast and\/or ovarian cancer patients, 58 <jats:italic>BRCA2<\/jats:italic> cancer patients, 602 non-<jats:italic>BRCA<\/jats:italic> patients and 328 other counselled patients. Breast cancer mean onset was 4.6\u00a0years earlier in <jats:italic>BRCA1<\/jats:italic> carriers compared to <jats:italic>BRCA2<\/jats:italic> (p\u2009=\u20090.07, a trend) and ovarian cancer onset almost 11\u00a0years earlier in <jats:italic>BRCA1<\/jats:italic> families (p\u2009&lt;\u20090.05). In <jats:italic>BRCA<\/jats:italic> families the onset of ovarian cancer was later than 40\u00a0years, and <jats:italic>BRCA2<\/jats:italic>-origin breast cancer was seen as late as 78\u00a0years. The <jats:italic>BRCA<\/jats:italic> PV (9%) increases the risk for same patient having both ovarian and breast cancer with a twofold risk when compared to non-<jats:italic>BRCA<\/jats:italic> group (4%) (95% CI p\u2009&lt;\u20090.05). Triple-negativity in <jats:italic>BRCA1<\/jats:italic> (42%) carriers is approximately 2.6 times vs more common than in <jats:italic>BRCA2<\/jats:italic> carriers (16%) (p\u2009&lt;\u20090.05). The risk ratio for bilateral breast cancer is approximately four times when compared <jats:italic>BRCA2<\/jats:italic> (17%) and other counselled patients\u2019 group (4%) (p\u2009&lt;\u20090.05). 27% southwestern <jats:italic>BRCA2<\/jats:italic>-families have a unique PV, and correspondingly 39% of <jats:italic>BRCA1<\/jats:italic>-families. The results of this analysis allow improved prediction of cancer risk in high-risk hereditary breast and ovarian families in southwestern Finland and improve long term follow-up programs. According to the result it could be justified to have the discussion about prophylactic salpingo-oophorectomy by the age of 40\u00a0years. The possibility of late breast cancer onset in <jats:italic>BRCA2<\/jats:italic> carriers supports the lifelong follow-up in <jats:italic>BRCA<\/jats:italic> carriers. Cancer onset is similar between <jats:italic>BRCA2<\/jats:italic> carries and non-<jats:italic>BRCA<\/jats:italic> high-risk families. This study evaluated mutation profile of <jats:italic>BRCA<\/jats:italic> in southwestern Finland. In this study genotype\u2013phenotype correlation was not found<\/jats:p>","DOI":"10.1038\/s41598-022-10519-y","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T09:17:05Z","timestamp":1650878225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland"],"prefix":"10.1038","volume":"12","author":[{"given":"Terhi Aino-Sofia","family":"Pallonen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salla Maria Matleena","family":"Lempi\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titta Kristiina","family":"Joutsiniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta Irmeli","family":"Aaltonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia Erika","family":"Pohjola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna Kristiina","family":"Kankuri-Tammilehto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"issue":"2","key":"10519_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65(2), 87\u2013108 (2015).","journal-title":"CA Cancer J. Clin."},{"key":"10519_CR2","volume-title":"Cancer Statistics Application","author":"Finnish Cancer Registry","year":"2020","unstructured":"Finnish Cancer Registry. Cancer Statistics Application (Finnish Cancer Registry, 2020)."},{"issue":"38","key":"10519_CR3","doi-asserted-by":"publisher","first-page":"6445","DOI":"10.1038\/sj.onc.1207714","volume":"23","author":"R Nagy","year":"2004","unstructured":"Nagy, R., Sweet, K. & Eng, C. Highly penetrant hereditary cancer syndromes. Oncogene 23(38), 6445\u20136470. https:\/\/doi.org\/10.1038\/sj.onc.1207714 (2004).","journal-title":"Oncogene"},{"issue":"2","key":"10519_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/0284186X.2018.1529428","volume":"58","author":"C Wendt","year":"2019","unstructured":"Wendt, C. & Margolin, S. Identifying breast cancer susceptibility genes\u2014A review of the genetic background in familial breast cancer. Acta Oncol. 58(2), 135\u2013146. https:\/\/doi.org\/10.1080\/0284186X.2018.1529428 (2019).","journal-title":"Acta Oncol."},{"issue":"8","key":"10519_CR5","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00439-013-1299-y","volume":"132","author":"L Melchor","year":"2013","unstructured":"Melchor, L. & Ben\u00edtez, J. The complex genetic landscape of familial breast cancer. Hum. Genet. 132(8), 845\u2013863. https:\/\/doi.org\/10.1007\/s00439-013-1299-y (2013).","journal-title":"Hum. Genet."},{"issue":"5","key":"10519_CR6","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1054\/bjoc.2000.1626","volume":"84","author":"P Vahteristo","year":"2001","unstructured":"Vahteristo, P., Eerola, H., Tamminen, A., Blomqvist, C. & Nevanlinna, H. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br. J. Cancer 84(5), 704\u2013708 (2001).","journal-title":"Br. J. Cancer"},{"key":"10519_CR7","first-page":"4695","volume":"46","author":"H Eerola","year":"2002","unstructured":"Eerola, H., Aittom\u00e4ki, K. & Nevanlinna, H. Genetic susceptibility to breast cancer. Finnish Med. J. 46, 4695\u20134701 (2002).","journal-title":"Finnish Med. J."},{"issue":"5","key":"10519_CR8","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/ijc.31841","volume":"144","author":"J Li","year":"2019","unstructured":"Li, J. et al. Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. Int. J. Cancer 144(5), 1195\u20131204. https:\/\/doi.org\/10.1002\/ijc.31841 (2019).","journal-title":"Int. J. Cancer"},{"issue":"18","key":"10519_CR9","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/jnci\/92.18.1529","volume":"92","author":"K Syrj\u00e4koski","year":"2000","unstructured":"Syrj\u00e4koski, K. et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J. Natl. Cancer Inst. 92(18), 1529\u20131531. https:\/\/doi.org\/10.1093\/jnci\/92.18.1529 (2000).","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10519_CR10","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.30498","volume":"123","author":"SS Buys","year":"2017","unstructured":"Buys, S. S. et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer 123(10), 1721\u20131730. https:\/\/doi.org\/10.1002\/cncr.30498 (2017).","journal-title":"Cancer"},{"issue":"23","key":"10519_CR11","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23), 2402\u20132416. https:\/\/doi.org\/10.1001\/jama.2017.7112 (2017).","journal-title":"JAMA"},{"issue":"11","key":"10519_CR12","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen, S. & Parmigiani, G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 25(11), 1329\u20131333. https:\/\/doi.org\/10.1200\/JCO.2006.09.1066 (2007).","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10519_CR13","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/jnci\/djm203","volume":"99","author":"YC Tai","year":"2007","unstructured":"Tai, Y. C., Domchek, S., Parmigiani, G. & Chen, S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 99(23), 1811\u20131814. https:\/\/doi.org\/10.1093\/jnci\/djm203 (2007).","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10519_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/cncr.29041","volume":"121","author":"J Mersch","year":"2015","unstructured":"Mersch, J. et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121(2), 269\u2013275. https:\/\/doi.org\/10.1002\/cncr.29041 (2015).","journal-title":"Cancer"},{"issue":"13","key":"10519_CR15","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1001\/jama.2014.5985","volume":"313","author":"TR Rebbeck","year":"2015","unstructured":"Rebbeck, T. R. et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13), 1347\u20131361. https:\/\/doi.org\/10.1001\/jama.2014.5985 (2015).","journal-title":"JAMA"},{"key":"10519_CR16","unstructured":"GeneReviews. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1247\/ (Accessed 20 June 2020)."},{"issue":"1","key":"10519_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","volume":"121","author":"K Metcalfe","year":"2019","unstructured":"Metcalfe, K. et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br. J. Cancer 121(1), 15\u201321. https:\/\/doi.org\/10.1038\/s41416-019-0446-1 (2019).","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10519_CR18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1634\/theoncologist.2016-0444","volume":"22","author":"R Tschernichovsky","year":"2017","unstructured":"Tschernichovsky, R. & Goodman, A. Risk-reducing strategies for ovarian cancer in BRCA mutation carriers: A balancing act. Oncologist 22(4), 450\u2013459. https:\/\/doi.org\/10.1634\/theoncologist.2016-0444 (2017).","journal-title":"Oncologist"},{"issue":"3","key":"10519_CR19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/jnci\/djy182","volume":"111","author":"M Terry","year":"2019","unstructured":"Terry, M., Daly, M. & Phillips, K. Y. Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk. J. Natl. Cancer Inst. 111(3), 331\u2013334 (2019).","journal-title":"J. Natl. Cancer Inst."},{"key":"10519_CR20","first-page":"1262","volume":"134","author":"A Auranen","year":"2018","unstructured":"Auranen, A. Perinn\u00f6llisen sy\u00f6p\u00e4alttiuden tunnistamisella on merkityst\u00e4 my\u00f6s gynekologisten sy\u00f6pien ehk\u00e4isyss\u00e4. Duodecim 134, 1262\u20131264 (2018).","journal-title":"Duodecim"},{"issue":"12","key":"10519_CR21","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/cancers10120524","volume":"10","author":"J Kotsopoulos","year":"2018","unstructured":"Kotsopoulos, J. BRCA mutations and breast cancer prevention. Cancers (Basel) 10(12), 524. https:\/\/doi.org\/10.3390\/cancers10120524 (2018).","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10519_CR22","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1158\/1078-0432.CCR-15-1465","volume":"22","author":"X Li","year":"2016","unstructured":"Li, X. et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: A meta-analysis and systematic review. Clin. Cancer Res. 22(15), 3971\u20133981. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1465 (2016).","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10519_CR23","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1200\/JCO.2005.02.7888","volume":"24","author":"LJ Pierce","year":"2006","unstructured":"Pierce, L. J. et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1\/2-associated stage I\/II breast cancer. J. Clin. Oncol. 24(16), 2437\u20132443. https:\/\/doi.org\/10.1200\/JCO.2005.02.7888 (2006).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10519_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nrclinonc.2016.191","volume":"14","author":"A George","year":"2017","unstructured":"George, A., Kaye, S. & Banerjee, S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat. Rev. Clin. Oncol. 14(5), 284\u2013296. https:\/\/doi.org\/10.1038\/nrclinonc.2016.191 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"31","key":"10519_CR25","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1200\/JCO.2015.63.0996","volume":"33","author":"ME Robson","year":"2015","unstructured":"Robson, M. E. et al. American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility. J. Clin. Oncol. 33(31), 3660\u20133667. https:\/\/doi.org\/10.1200\/JCO.2015.63.0996 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10519_CR26","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.3390\/cancers12071929","volume":"12","author":"R Manchanda","year":"2020","unstructured":"Manchanda, R., Sun, S. & Patel, S. Economic evaluation of population-based BRCA1\/BRCA2 mutation testing across multiple countries and health. Cancer 12(7), 1929. https:\/\/doi.org\/10.3390\/cancers12071929 (2020).","journal-title":"Cancer"},{"issue":"7","key":"10519_CR27","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.19.01907","volume":"38","author":"X Yang","year":"2020","unstructured":"Yang, X. et al. Cancer risks associated with germline PALB2 pathogenic variants: An international study of 524 families. J. Clin. Oncol. 38(7), 674\u2013685. https:\/\/doi.org\/10.1200\/JCO.19.01907 (2020).","journal-title":"J. Clin. Oncol."},{"key":"10519_CR28","first-page":"880","volume":"14","author":"M Kankuri-Tammilehto","year":"2019","unstructured":"Kankuri-Tammilehto, M., Vihinen, P. & Schleutker, J. Heredity of cancer. Finnish Med. J. 14, 880\u2013886 (2019).","journal-title":"Finnish Med. J."},{"issue":"1","key":"10519_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10549-017-4388-0","volume":"166","author":"JI Kiiski","year":"2017","unstructured":"Kiiski, J. I. et al. FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population. Breast Cancer Res. Treat. 166(1), 217\u2013226. https:\/\/doi.org\/10.1007\/s10549-017-4388-0 (2017).","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10519_CR30","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.molonc.2010.04.011","volume":"4","author":"N Mavaddat","year":"2010","unstructured":"Mavaddat, N., Antoniou, A. C., Easton, D. F. & Garcia-Closas, M. Genetic susceptibility to breast cancer. Mol. Oncol. 4(3), 174\u2013191. https:\/\/doi.org\/10.1016\/j.molonc.2010.04.011 (2010).","journal-title":"Mol. Oncol."},{"issue":"10","key":"10519_CR31","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/sj.ejhg.5200717","volume":"9","author":"R Barkardottir","year":"2001","unstructured":"Barkardottir, R. et al. Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families. Eur. J. Hum. Genet. 9(10), 773\u2013779 (2001).","journal-title":"Eur. J. Hum. Genet."},{"key":"10519_CR32","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1093\/hmg\/6.13.2309","volume":"6","author":"P Vehmanen","year":"1997","unstructured":"Vehmanen, P. et al. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum. Mol. Genet. 6, 2309 (1997).","journal-title":"Hum. Mol. Genet."},{"key":"10519_CR33","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1086\/301880","volume":"62","author":"P Huusko","year":"1998","unstructured":"Huusko, P. et al. Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. Am. J. Hum. Genet. 62, 1544 (1998).","journal-title":"Am. J. Hum. Genet."},{"issue":"10","key":"10519_CR34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/sj.ejhg.5200529","volume":"8","author":"L Sarantaus","year":"2000","unstructured":"Sarantaus, L. et al. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur. J. Hum. Genet. 8(10), 757\u2013763 (2000).","journal-title":"Eur. J. Hum. Genet."},{"key":"10519_CR35","first-page":"772","volume":"47","author":"M Thomassen","year":"2008","unstructured":"Thomassen, M. et al. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and\/or ovarian cancer. Actancology 47, 772\u2013777 (2008).","journal-title":"Actancology"},{"key":"10519_CR36","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.ejca.2007.04.023","volume":"43","author":"P Moller","year":"2007","unstructured":"Moller, P. et al. Genetic epidemiology of BRCA mutations\u2014Family history detects less than 50% of the mutation carriers. Eur. J. Cancer 43, 1713\u20131717 (2007).","journal-title":"Eur. J. Cancer"},{"key":"10519_CR37","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/humu.23406","volume":"35","author":"T Rebbeck","year":"2018","unstructured":"Rebbeck, T. et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum. Mutat. 35, 593 (2018).","journal-title":"Hum. Mutat."},{"issue":"5","key":"10519_CR38","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/ijc.31841","volume":"144","author":"J Li","year":"2019","unstructured":"Li, J. et al. Cancer therapy and prevention open access prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. Int. J. Cancer 144(5), 1195\u20131204 (2019).","journal-title":"Int. J. Cancer"},{"key":"10519_CR39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10689-004-7023-2","volume":"4","author":"B Kremeyer","year":"2005","unstructured":"Kremeyer, B. et al. The BRCA1 exon 13 duplication in the Swedish population. Fam. Cancer 4, 191\u2013194 (2005).","journal-title":"Fam. Cancer"},{"key":"10519_CR40","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/nm1196-1179","volume":"2","author":"P Tonin","year":"1996","unstructured":"Tonin, P. et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat. Med. 2, 1179\u20131183 (1996).","journal-title":"Nat. Med."},{"key":"10519_CR41","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.canlet.2010.07.013","volume":"298","author":"AG Iyevleva","year":"2010","unstructured":"Iyevleva, A. G. et al. Non-founder BRCA1 mutations in Russian breast cancer patients. Cancer Lett. 298, 258\u2013263 (2010).","journal-title":"Cancer Lett."},{"key":"10519_CR42","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1399-0004.2009.01277.x","volume":"76","author":"P Ghadirian","year":"2009","unstructured":"Ghadirian, P. et al. The contribution of founder mutations to earlyonset breast cancer in French-Canadian women. Clin. Genet. 76, 421\u2013426 (2009).","journal-title":"Clin. Genet."},{"issue":"1","key":"10519_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.6004\/jnccn.2017.0003","volume":"15","author":"MB Daly","year":"2017","unstructured":"Daly, M. B. et al. NCCN guidelines insights: Genetic\/familial high-risk assessment: Breast and ovarian, version 2.2017. J. Natl. Compr. Cancer Netw. 15(1), 9\u201320. https:\/\/doi.org\/10.6004\/jnccn.2017.0003 (2017).","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"8","key":"10519_CR44","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1136\/jmedgenet-2018-105313","volume":"55","author":"X Yang","year":"2018","unstructured":"Yang, X. et al. Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. J. Med. Genet. 55(8), 546\u2013554. https:\/\/doi.org\/10.1136\/jmedgenet-2018-105313 (2018).","journal-title":"J. Med. Genet."},{"issue":"1","key":"10519_CR45","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1038\/s41467-020-19966-5","volume":"11","author":"N Mars","year":"2020","unstructured":"Mars, N. et al. The role of polygenic risk and susceptibility genes in breast cancer over the course of life. Nat. Commun. 11(1), 6383. https:\/\/doi.org\/10.1038\/s41467-020-19966-5 (2020).","journal-title":"Nat. Commun."},{"key":"10519_CR46","unstructured":"Finnish Breast Cancer Group. Rintasy\u00f6v\u00e4n valtakunnallinen diagnostiikka- ja hoitosuositus 2019. (Accessed 20 June)."},{"issue":"4","key":"10519_CR47","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1200\/JCO.2014.56.6232","volume":"33","author":"XA Phi","year":"2015","unstructured":"Phi, X. A. et al. Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age \u2265 50 years: Evidence from an individual patient data meta-analysis. J. Clin. Oncol. 33(4), 349\u2013356. https:\/\/doi.org\/10.1200\/JCO.2014.56.6232 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"suppl 5","key":"10519_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/annonc\/mdw327","volume":"27","author":"S Paluch-Shimon","year":"2016","unstructured":"Paluch-Shimon, S. et al. Prevention and screening in BRCA mutation carriers and other breast\/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann. Oncol. 27(suppl 5), 103\u2013110. https:\/\/doi.org\/10.1093\/annonc\/mdw327 (2016).","journal-title":"Ann. Oncol."},{"issue":"Suppl 6","key":"10519_CR49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/annonc\/mds187","volume":"23","author":"P Boyle","year":"2012","unstructured":"Boyle, P. Triple-negative breast cancer: Epidemiological considerations and recommendations. Ann. Oncol. 23(Suppl 6), 7\u201312. https:\/\/doi.org\/10.1093\/annonc\/mds187 (2012).","journal-title":"Ann. Oncol."},{"key":"10519_CR50","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulces","year":"2010","unstructured":"Foulces, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938\u20131948. https:\/\/doi.org\/10.1056\/NEJMra1001389 (2010).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10519_CR51","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10549-007-9709-2","volume":"110","author":"M Schaapveld","year":"2008","unstructured":"Schaapveld, M. et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: A population based study in the Netherlands. Breast Cancer Res. Treat. 110(1), 189\u2013197. https:\/\/doi.org\/10.1007\/s10549-007-9709-2 (2008).","journal-title":"Breast Cancer Res. Treat."},{"issue":"12","key":"10519_CR52","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1200\/JCO.2004.04.033","volume":"22","author":"K Metcalfe","year":"2004","unstructured":"Metcalfe, K. et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 22(12), 2328\u20132335. https:\/\/doi.org\/10.1200\/JCO.2004.04.033 (2004).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10519_CR53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cancergencyto.2005.05.014","volume":"163","author":"E Laurila","year":"2005","unstructured":"Laurila, E., Syrj\u00e4koski, K., Holli, K., Kallioniemi, A. & Karhu, R. Search for large genomic alterations of the BRCA1 gene in a Finnish population. Cancer Genet. Cytogenet. 163(1), 57\u201361. https:\/\/doi.org\/10.1016\/j.cancergencyto.2005.05.014 (2005).","journal-title":"Cancer Genet. Cytogenet."},{"issue":"4","key":"10519_CR54","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1002\/cam4.2000","volume":"8","author":"CF Singer","year":"2019","unstructured":"Singer, C. F. et al. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients. Cancer Med. 8(4), 1875\u20131881. https:\/\/doi.org\/10.1002\/cam4.2000 (2019).","journal-title":"Cancer Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10519-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10519-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10519-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T01:56:04Z","timestamp":1669341364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10519-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10519"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10519-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"assertion":[{"value":"11 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6704"}}